Phase I studies of a new biosimilar filgrastim product (Zarzio) published

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Sign up
eng / esp

Phase I studies of a new biosimilar filgrastim product (Zarzio) published

Biosimilars/Research | Posted 04/06/2010 0 Post your comment

Zarzio (Sandoz GmbH), a biosimilar recombinant human granulocyte colony-stimulating factor (filgrastim), was evaluated in healthy volunteers in four phase I studies and in neutropenic patients in a phase III study.

The four phase I randomised, double-blind, cross-over, single or multiple dose studies enrolled 146 healthy volunteers (81 male and 65 female). Volunteers were treated with either Zarzio (Sandoz GmbH), or the reference product, Neupogen (Amgen GmbH), administered via both the SC and IV routes.

Pharmacodynamic analysis

The filagrastim-induced response was assessed in terms of the absolute neutrophil count (ANC), spanning the linear (1–10 mg/kg) portion of the dose-response curve, and CD34+ cells (dose range 2.5–10 mg/kg, after multiple dosing).

The mean ANC-time profiles were superimposable for all dose levels and routes. After SC injection, the ANC increase was reversible and returned to baseline levels ~48 hours after the last administration.

After seven days of SC administration, both products exhibited a clear dose-dependent response. The mean Zarzio area under the effect-time curve for ANC increased from 4.2 hours 106/mL for the 2.5 mg/kg group to 5.2 and to 6.5 hours 106/mL for the 5 and 10 mg/kg dose groups, respectively.

The CD34+ counts increased with increasing dose for both products with confidence intervals (CIs) well within the predefined equivalence boundaries.

Pharmacokinetic analysis

Both products showed similar pharmacokinetic characteristics. The 90% CIs for area under the curve from time of administration until the last scheduled blood sampling and maximum serum concentration fell well within the predefined bioequivalence limits of 80–125%.

The phase I studies demonstrated biosimilarity with respect to the pharmacokinetics and pharmacodynamics of various doses of Zarzio and the reference product, Neupogen (Amgen GmbH), in healthy volunteers, administered via both the SC and IV routes.

(link to Development of a new biosimilar filgrastim product (Zarzio) and Phase III study of a new biosimilar filgrastim product (Zarzio) published)

Reference:

Gascon P, Fuhr U, Sorgel F et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2009 Dec 17. doi: 10.1093/annonc/mdp574